BRIEF published on 11/04/2024 at 11:51, 1 year 5 months ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 5 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 5 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 5 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 5 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 5 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 5 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 5 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year 9 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 9 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 04/10/2026 at 13:00, 40 minutes ago Gamma Resources Adopts Semi-Annual Financial Reporting
Published on 04/10/2026 at 13:00, 40 minutes ago GMV Minerals Announces Drill Mobilization at the Mexican Hat Gold Deposit in S.E. Arizona
Published on 04/10/2026 at 02:15, 11 hours 25 minutes ago Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 12 hours 35 minutes ago Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 13 hours 40 minutes ago Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/10/2026 at 13:28, 11 minutes ago Ethnosports 2027 unveiled as a global vision for traditional sports
Published on 04/10/2026 at 11:45, 1 hour 55 minutes ago EQS-Adhoc: Bastei Lübbe AG lowers revenue and EBIT forecast for the 2025/2026 financial year
Published on 04/10/2026 at 11:07, 2 hours 33 minutes ago NOTICE OF CALLING OF THE ORDINARY SHAREHOLDERS’ MEETING
Published on 04/10/2026 at 10:45, 2 hours 55 minutes ago "In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026
Published on 04/10/2026 at 11:07, 2 hours 33 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 31 mars 2026
Published on 04/10/2026 at 10:00, 3 hours 40 minutes ago Recticel Group akoestische materialen gebruikt in NASA’s Artemis II-missie
Published on 04/10/2026 at 10:00, 3 hours 40 minutes ago Recticel Group’s acoustic materials used in NASA’s Artemis II-mission
Published on 04/10/2026 at 08:45, 4 hours 55 minutes ago Imerys-communique-presse-accord-ferme_10-04-2026_VFR
Published on 04/10/2026 at 08:45, 4 hours 55 minutes ago Imerys-press-release-binding-agreement_10-04-2026_VENG
